Colonial Trust Advisors’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$58.3K Buy
418
+182
+77% +$25.5K ﹤0.01% 334
2025
Q4
$29K Sell
236
-43
-15% -$5.23K ﹤0.01% 407
2025
Q3
$31K Sell
279
-6
-2% -$682 ﹤0.01% 389
2025
Q2
$31.6K Buy
285
+2
+0.7% +$213 ﹤0.01% 391
2025
Q1
$31.8K Buy
283
+213
+304% +$22K ﹤0.01% 387
2024
Q4
$6.47K Buy
70
+52
+289% +$4.68K ﹤0.01% 535
2024
Q3
$1.51K Hold
18
﹤0.01% 694
2024
Q2
$1.24K Sell
18
-21
-54% -$1.4K ﹤0.01% 698
2024
Q1
$2.86K Sell
39
-38
-49% -$2.92K ﹤0.01% 759
2023
Q4
$6.24K Buy
77
+5
+7% +$389 ﹤0.01% 579
2023
Q3
$5.4K Hold
72
﹤0.01% 598
2023
Q2
$5.55K Hold
72
﹤0.01% 610
2023
Q1
$5.97K Sell
72
-7
-9% -$580 ﹤0.01% 591
2022
Q4
$6.78K Buy
+79
New +$6.26K ﹤0.01% 572

Other funds holding GILD

Colonial Trust Advisors's GILD Position: Q1 2026 in Review

Colonial Trust Advisors increased its Gilead Sciences (GILD) stake by 77% in Q1 2026, buying an estimated $25.5K and bringing the position to 418 shares worth $58.3K. The position accounts for ﹤0.01% of the portfolio, ranked #334.

Colonial Trust Advisors first reported a position in GILD in Q4 2022 and has held it in 14 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Colonial Trust Advisors held 418 shares of Gilead Sciences worth $58.3K as of Q1 2026.
  • Colonial Trust Advisors bought 182 Gilead Sciences shares in Q1 2026, an estimated $25.5K.
  • Gilead Sciences made up ﹤0.01% of Colonial Trust Advisors's portfolio in Q1 2026, its #334 holding.
  • Colonial Trust Advisors first reported a position in Gilead Sciences in Q4 2022 and has held it in 14 quarters since.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Colonial Trust Advisors's 13F filing for Q1 2026, filed 12 May 2026.